New antibody tested against Tough-to-Treat blood cancers
NCT ID NCT04824794
Summary
This early-phase study tested a new antibody drug called GEN3014 in people with multiple myeloma and other blood cancers that had returned or stopped responding to standard treatments. The main goals were to find a safe dose and see if the drug showed any early signs of fighting the cancer. The study was terminated and did not reach its later phases.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ARENSIA Exploratory Medicine LLC
Tbilisi, Georgia
-
Aalborg Universitet
Aalborg, Denmark
-
Ahepa University General hospital
Thessaloniki, Greece
-
Alexandra General Hospital
Athens, Greece
-
Arensia Exploratory Medicine
Kyiv, Ukraine
-
Auckland Cancer Trials Centre
Grafton, New Zealand
-
Beacon Hospital
Petaling Jaya, Malaysia
-
CHRU de Lille
Lille, France
-
CHRU de Nantes
Nantes, France
-
Chonnam National University Hwasun Hospital
Gwangju, South Korea
-
Christchurch Hospital
Christchurch, New Zealand
-
Erasmus MC
Rotterdam, Netherlands
-
Evangelismos Hospital NKUA
Athens, Greece
-
FNO - Fakultni nemocnice Ostrava
Poruba, Czechia
-
Fakultni Nemocnice Brno
Brno, Czechia
-
Fakultni Nemocnice Hradec Kralove FNHK
Nový Hradec Králové, Czechia
-
Fakultni Nemocnice Olomouc (FNOL)
Olomouc, Czechia
-
Gachon University Gil Medical Center
Seongnam, South Korea
-
Hospital Ampang
Ampang, Malaysia
-
Hospital Sultanah Aminah
Johor Bahru, Malaysia
-
Hospital Umum Sarawak
Kuching, Malaysia
-
Institute of Oncology, ARENSIA Exploratory Medicine
Chisinau, Moldova
-
John Theurer Cancer Center
Hackensack, New Jersey, 07601, United States
-
Karolinska Institute
Huddinge, Sweden
-
Klinika za hematologiju KCUS
Sarajevo, Bosnia and Herzegovina
-
Maastricht UMC
Maastricht, Netherlands
-
Makati Medical Center
Makati City, Philippines
-
Medical college of Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
North Shore Hospital
Takapuna, New Zealand
-
Northern Health
Epping, Australia
-
Palmerston North Hospital
Palmerston North, New Zealand
-
Pratia MCM
Krakow, Poland
-
Pratia Onkologia Katowice
Katowice, Poland
-
Pusan National University Hospital PNUH
Pusan, South Korea
-
Royal Prince Alfred Hospital
Sydney, Australia
-
Samsung Medical Center
Seoul, South Korea
-
Seoul National University Hospital
Seoul, South Korea
-
Szabolcs-Szatmar-Bereg County Hospitals and University Hospital, Josa Andras University Hospital
Nyíregyháza, Hungary
-
The Alfred Hospital
Melbourne, Australia
-
UKC - University Clinical Center Tuzla
Tuzla, Bosnia and Herzegovina
-
UMC Utrecht
Utrecht, Netherlands
-
Universitetssjukhuset i Lund
Lund, Sweden
-
University Centrum Kliniczne
Gdansk, Poland
-
University Clinic of Hematology
Skopje, North Macedonia
-
University Clinical Center of the Republic of the Srpska
Banja Luka, Bosnia and Herzegovina
-
University General Hospital of Patras
Rio, Greece
-
University Hospital of Salamanca
Salamanca, Spain
-
University Hospitals Cleveland Medical Center
Cleveland, Ohio, 44106, United States
-
University of Navarra
Pamplona, Spain
-
Vejle Hospital
Vejle, Denmark
-
Vseobecna fakultni nemocnice
New Town, Czechia
-
Wroclaw Medical University
Wroclaw, Poland
Conditions
Explore the condition pages connected to this study.